The current and future burden of late-onset dementia in the United Kingdom: Estimates and interventions

Alzheimer's and Dementia

Volumn 13, Issue 1, 2017, Pages 38-44

  Lewis, Fraser I ^a   Torgerson, Paul R ^b  

^a Office of Health Economics   (United Kingdom)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Disease burden; Epidemiology; Mathematical model

Indexed keywords

AGED; ARTICLE; CONTROLLED STUDY; DEMENTIA; FEMALE; GLOBAL DISEASE BURDEN; HUMAN; INCIDENCE; LATE ONSET DISORDER; MAJOR CLINICAL STUDY; MALE; POPULATION PROJECTION; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY ADJUSTED LIFE YEAR; UNITED KINGDOM; VERY ELDERLY; COST OF ILLNESS; DISABLED PERSON; HEALTH CARE PLANNING; PREVALENCE; PSYCHOLOGY; RETROSPECTIVE STUDY; THEORETICAL MODEL;

COMMUNITY HEALTH PLANNING; COST OF ILLNESS; DEMENTIA; DISABLED PERSONS; FEMALE; HUMANS; LATE ONSET DISORDERS; MALE; MODELS, THEORETICAL; PREVALENCE; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; UNITED KINGDOM;

EID: 84970003874     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.03.013     Document Type: Article

References (28)

1. [1] World Health Organization (WHO). Good health adds life to years: Global brief for World Health Day 2012. Available at: http://whqlibdoc.who.int/hq/2012/WHO_DCO_WHD_2012.2_eng.pdf. Accessed January 20, 2016.
2. [2] Alzheimer's Disease International (ADI). World Alzheimer Report 2015 The Global Impact of Dementia an analysis of prevalence, incidence, cost and trends. Available at: http://www.alz.co.uk/research/WorldAlzheimerReport2015.pdf. Accessed January 20, 2016.
3. [3] Wu, Y.T., Fratiglioni, L., Matthews, F.E., Lobo, A., Breteler, M.M.B., Skoog, I., et al. Dementia in western Europe: epidemiological evidence and implications for policy making. Lancet Neurol 15 (2016), 116–124.
4. [4] Norton, S., Matthews, F.E., Brayne, C., A commentary on studies presenting projections of the future prevalence of dementia. BMC Public Health, 13, 2013, 1.
5. [5] Vickland, V., McDonnell, G., Werner, J., Draper, B., Low, L.-F., Brodaty, H., In silico modeling systems: learning about the prevalence and dynamics of dementia through virtual experimentation. Alzheimers Dement 7 (2011), e77–e83.
6. [6] Alzheimer's Association. Changing the Trajectory of Alzheimer's Disease: How a Treatment by 2025 Saves Lives and Dollars. Available at: http://www.alz.org/documents_custom/trajectory.pdf. Accessed January 20, 2016.
7. [7] OHE. The Trajectory of Dementia in the UK - Making a Difference. Available at: https://www.ohe.org/publications/trajectory-dementia-uk-making-difference. Accessed January 20, 2016.
8. [8] Horton, R., GBD 2010: understanding disease, injury, and risk. Lancet 380 (2012), 2053–2054.
9. [9] Murray, C.J.L., Richards, M.A., Newton, J.N., Fenton, K.A., Anderson, H.R., Atkinson, C., et al. UK health performance: findings of the Global Burden of Disease Study 2010. Lancet 381 (2013), 997–1020.
10. [10] Hethcote, H.W., The mathematics of infectious diseases. SIAM Rev 42 (2000), 599–653.
11. [11] The Alzheimer's Society. Dementia UK: Update. Available at: http://www.alzheimers.org.uk/site/scripts/download_info.php?fileID=2323. Accessed January 20, 2016.
12. [12] Cummings, J.L., Morstorf, T., Zhong, K., Alzheimer's disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res Ther, 6, 2014, 37.
13. [13] alzinfo.org. Available at: https://www.alzinfo.org/articles/solanezumab-tested-large-trial-early-alzheimers/. Accessed January 20, 2016.
14. [14] Businesswire.com. Available at: http://www.businesswire.com/news/home/20150320005170/en/Biogen-Idec-Presents-Positive-Interim-Results-Phase#.Vbs5McBViko. Accessed January 20, 2016.
15. [15] alzheimersnewstoday.com. Available at: http://alzheimersnewstoday.com/2015/03/18/clinical-trial-reveals-promising-brain-therapeutic-drug-for-the-pre-dementia-stage-of-alzheimers-disease/. Accessed January 20, 2016.
16. [16] Bakker, A., Albert, M.S., Krauss, G., Speck, C.L., Gallagher, M., Response of the medial temporal lobe network in amnestic mild cognitive impairment to therapeutic intervention assessed by fMRI and memory task performance. Neuroimage Clin 7 (2015), 688–698.
17. [17] Paul, S.M., Mytelka, D.S., Dunwiddie, C.T., Persinger, C.C., Munos, B.H., Lindborg, S.R., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 9 (2010), 203–214.
18. [18] HM Government. Life Science Competitiveness Indicators. Available at: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/418305/BIS-15-249-life-science-competitiveness-indicators.pdf. Accessed January 20, 2016.
19. [19] Xie, J., Brayne, C., Matthews, F.E., Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up. BMJ 336 (2008), 258–262.
20. [20] Kot M. Elements of Mathematical Ecology. Cambridge Univ Press, UK. http://dx.doi.org/10.1017/CBO9780511608520.
21. [21] Keyfitz, B.L., Keyfitz, N., The McKendrick partial differential equation and its uses in epidemiology and population study. Math Comput Model 26 (1997), 1–9.
22. [22] Kermack, W.O., McKendrick, A.G., Contribution to the mathematical theory of epidemics. Proc R Soc Lond 115 (1927), 700–721.
23. [23] Barendregt, J.J., van Oortmarssen, G.J., Vos, T., Murray, C.J., A generic model for the assessment of disease epidemiology: the computational basis of DisMod II. Popul Health Metr, 1, 2003, 4.
24. [24] James, B.D., Leurgans, S.E., Hebert, L.E., Scherr, P.A., Yaffe, K., Bennett, D.A., Contribution of Alzheimer disease to mortality in the United States. Neurology 82 (2014), 1045–1050.
25. [25] Ferri, C.P., Prince, M., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., et al. Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005), 2112–2117.
26. [26] Matthews, F.E., Arthur, A., Barnes, L.E., Bond, J., Jagger, C., Robinson, L., et al. A two-decade comparison of prevalence of dementia in individuals aged 65 years and older from three geographical areas of England: results of the Cognitive Function and Ageing Study I and II. Lancet 382 (2013), 1405–1412.
27. [27] Salomon, J.A., Vos, T., Hogan, D.R., Gagnon, M., Naghavi, M., Mokdad, A., et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 380 (2012), 2129–2143.
28. [28] Devleesschauwer, B., Haagsma, J.A., Angulo, F.J., Bellinger, D.C., Cole, D., Doepfer, D., et al. Methodological Framework for World Health Organization Estimates of the Global Burden of Foodborne Disease. PLoS One, 10, 2015, e0142498.